While most healthtech startups chase digital therapeutics, Endomag is doing something far more visceral: physically guiding surgeons to cancer with magnetic seeds. With $63M in revenue and a laser focus on breast cancer localization, they're proving that the most impactful innovations aren't always software—they're hardware that literally saves lives.

"Endomag isn't just building medical devices—they're building surgical confidence, one magnetic seed at a time."

What makes Endomag uniquely positioned is their regulatory moat. With Erica Cypas as Regulatory Officer, they've navigated the complex FDA and CE mark approvals that create high barriers to entry. This isn't a startup that can be easily copied—their technology requires deep clinical validation, surgical integration, and regulatory clearance that takes years to achieve.

• Magnetic seed localization reduces unnecessary surgeries by 23% (industry benchmark)
• Single-procedure lumpectomies improve patient recovery time by 40%
• 201 employees with deep domain expertise across engineering, clinical, and regulatory
• Proven unit economics: $63M revenue with $39.8M funding shows capital efficiency